Interstitial Cystitis Treatment Market to Witness Growth by 2030 | Key Companies includes – Kyorin Pharmaceutical, UCB Pharma, Lipella, Grünenthal, Astellas, Seikagaku, and Others

October 20 11:48 2021
Interstitial Cystitis Treatment Market to Witness Growth by 2030 | Key Companies includes - Kyorin Pharmaceutical, UCB Pharma, Lipella, Grünenthal, Astellas, Seikagaku, and Others
Delveinsight Business Research LLP
DelveInsight’s “Interstitial Cystitis Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Interstitial Cystitis Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Interstitial Cystitis market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Interstitial Cystitis Market

Interstitial Cystitis: An Overview

Interstitial Cystitis (IC), also called as Painful Bladder Syndrome, is a chronic condition causing bladder pressure, bladder pain and sometimes pelvic pain. The pain ranges from mild discomfort to severe levels. The bladder is a hollow, muscular organ that stores urine, which expands until it is full and then gives signals to the brain that it is time to urinate, communicating through the pelvic nerves; this creates the urge to urinate for most people. 

Interstitial Cystitis Market Key Facts

  • The market size of Interstitial Cystitis in the seven major markets was found to be USD 1,599 Million in 2017, which is expected to increase during the study period (2017–2030).

  • The United States accounted for the largest market size of Interstitial Cystitis, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

  • Interstitial Cystitis varies among men and women. Women are more at the risk of disease, with a ratio of 9:1.2 (female: male).

  • The total diagnosed prevalent population of Interstitial Cystitis in the 7 major markets was found to be 2,264,118 in 2017, whereas the diagnosed prevalent cases of Interstitial Cystitis patients in the United States were found to be 1,459,502 in 2017.

  • The prevalent population of Interstitial Cystitis in the United States was found to be 5,838,009 in 2017. 

Get FREE sample copy at: Interstitial Cystitis Therapeutics Market

Key Benefits of Interstitial Cystitis Market Report

  • The report provides an in-depth analysis of Interstitial Cystitis Market Size and Share till 2030 in the seven major markets.

  • The report will help in developing business strategies by understanding the Interstitial Cystitis Market Trends, key players, and ongoing developments that shape and drive the market growth in the upcoming years.

  • It covers Interstitial Cystitis current treatment practices, emerging drugs, market share of the individual therapies in the 7MM.

  • The report provides a detailed assessment of the Interstitial Cystitis market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Interstitial Cystitis Market 

The Interstitial Cystitis market size is expected to increase during the forecast period owing to the rise in the number of prevalent cases of Interstitial Cystitis.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Interstitial Cystitis market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Interstitial Cystitis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Interstitial Cystitis Epidemiology

The epidemiology section covers insights about the historical and current Interstitial Cystitis patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Interstitial Cystitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Interstitial Cystitis market or expected to get launched in the market during the study period. The analysis covers Interstitial Cystitis market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Interstitial Cystitis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

The dynamics of the Interstitial Cystitis market is anticipated to change in the coming years owing to the improvement in the research and development activities so that the market comprises efficient treatment options. The launch of emerging therapies is expected during the forecast period.

Some of the key companies in the Interstitial Cystitis market include:

  • Kyorin Pharmaceutical

  • UCB Pharma

  • Lipella Pharmaceuticals

  • Grünenthal

  • Astellas Pharma

  • Seikagaku Corporation

And others.

Interstitial Cystitis therapies covered in the report include 

  • KRP-116D

  • SI-722

  • ASP6294

  • LP-08

  • GRT6010

  • Certolizumab pegol (Cimzia)

And others.

Request for Sample @ Interstitial Cystitis Emerging Therapies and Key Companies

Table of Content

1. Key Insights

2. Executive Summary 

3. Interstitial Cystitis Competitive Intelligence Analysis

4. Interstitial Cystitis Market Overview at a Glance

5. Interstitial Cystitis Disease Background and Overview

6. Interstitial Cystitis Patient Journey

7. Interstitial Cystitis Epidemiology and Patient Population

8. Interstitial Cystitis Treatment Algorithm, Current Treatment, and Medical Practices

9. Interstitial Cystitis Unmet Needs

10. Key Endpoints of Interstitial Cystitis Treatment

11. Interstitial Cystitis Marketed Products

12. Interstitial Cystitis Emerging Therapies

13. Interstitial Cystitis Seven Major Market Analysis

14. Attribute Analysis

15. Interstitial Cystitis Market Outlook (7 major markets)

16. Interstitial Cystitis Access and Reimbursement Overview

17. KOL Views on the Interstitial Cystitis Market.

18. Interstitial Cystitis Market Drivers

19. Interstitial Cystitis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at:

Latest Reports By DelveInsight

Total Knee Arthroplasty Market

DelveInsight’s ‘Total Knee Arthroplasty -Market Insights, Competitive Landscape and Market Forecast-2026’ report delivers an in-depth understanding of Total Knee Arthroplasty and the historical and forecasted Total Knee Arthroplasty market trends in the US, EU5 (Germany, France, Spain, Italy, and the United Kingdom) and Japan.

Healthcare Blogs

Gene Therapy for Skin Diseases

Gene therapy is coming out as a revolutionary mechanism to treat rare skin diseases and autoimmune skin conditions that were prior considered impossible to cure. Globally, several key pharma and biotech companies are constantly working to develop gene therapies associated with dermatology diseases including Krystal Biotech, Castle Creek Biosciences, Almirall, Abeona Therapeutics, Fibrocell Science, Amryt Pharma, Sterna Biologicals, Temprian Therapeutics, Holostem Terapie Avanzate, Azitra, Novartis, AVITA Medical, and others. Read More: Gene Therapies in Dermatology

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States